Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levamlodipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 0.86 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.86 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.86 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.86 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.86 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.86 |
| ▸ | HTR1A | P08908 | 2/20 | 0.86 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.86 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.86 |
| ▸ | DRD1 | P21728 | 2/20 | 0.86 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.86 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.86 |
| ▸ | DRD3 | P35462 | 2/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.86 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.86 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.86 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.86 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.86 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.86 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amlodipine SCHEMBL3399451 | 0.99 | TBXA2R (0.88) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL5182627 | 0.99 | TBXA2R (0.88) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Levamlodipine SCHEMBL3403387 | 0.99 | TBXA2R (0.88) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL2762990 | 0.95 | TBXA2R (0.81) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL8176202 | 0.95 | ADRA1A (0.81) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL6666635 | 0.94 | TBXA2R (0.98) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL6650712 | 0.94 | TBXA2R (0.98) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL6664321 | 0.94 | TBXA2R (0.98) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Levamlodipine SCHEMBL6666638 | 0.94 | TBXA2R (0.98) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Levamlodipine SCHEMBL6664327 | 0.94 | TBXA2R (0.98) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362263-B2 | Crystalline S-(−)-amlodipine adipic acid salt anhydrous and preparation method thereof | CJ CHEILJEDANG CORPORATION (KR) | 2013-01-29 | — | — | US | disclosed |
| US-20100069642-A1 | CRYSTALLINE S-(-)-AMLODIPINE ADIPIC ACID SALT ANHYDROUS AND PREPARATION METHOD THEREOF | CJ CHEILJEDANG CORPORATION (KR) | 2010-03-18 | — | — | US | disclosed |
| EP-2077994-A1 | CRYSTALLINE S-(-)-AMLODIPINE ADIPIC ACID SALT ANHYDROUS AND PREPARATION METHOD THEREOF | CJ CheilJedang Corporation (KR) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008091085-A1 | CRYSTALLINE S-(-)-AMLODIPINE OROTATE ANHYDROUS AND PREPARATION METHOD THEREOF | CJ CHEILJEDANG CORPORATION (KR) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008069469-A1 | CRYSTALLINE S-(-)-AMLODIPINE CAMSYLATE ANHYDRIDE AND PREPARATION METHOD THEREOF | CJ CORPORATION (KR) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008060093-A1 | CRYSTALLINE S-(-)-AMLODIPINE MALEIC ACID SALT ANHYDRIDE AND PREPARATION METHOD THEREOF | CJ CHEILJEDANG CORPORATION (KR) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008054096-A1 | CRYSTALLINE S-(-)-AMLODIPINE ADIPIC ACID SALT ANHYDROUS AND PREPARATION METHOD THEREOF | CJ CHEILJEDANG CORPORATION (KR) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069642-A1 | CRYSTALLINE S-(-)-AMLODIPINE ADIPIC ACID SALT ANHYDROUS AND PREPARATION METHOD THEREOF | ADIPOR1, ADIPOR2, FABP4 | CACNA1C 8/4885TBXA2R 2278/4885ADRA1A 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.